Histamine-2 Receptor Antagonists as Immunomodulators: New Therapeutic Views?

References

• Sampson H A, Broadbent K R, Benhisel-Broadbent J. Spontaneous release of histamine from basophils and histamine-releasing factors in patients with atopic dermatitis and food hypersensitivity. N Engl J Med 1989; 321: 328–32
   Google Scholar
• Pearce F L. Biological effects of histamine: an overview. Agents Actions 1991; 33: 4–7
   PubMedGoogle Scholar
• Beer D J, Rocklin R E. Histamine modulation of lymphocyte biology: membrane receptors, signal transduction, and functions. Crit Rev Immunol 1987; 7: 55–91
   PubMedGoogle Scholar
• Nielsen H J. The effect of histamine type-2 receptor antagonists on posttraumatic immune competence. Dan Med Bull 1995; 42: 162–74
   PubMedGoogle Scholar
• Hellstrand K, Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H-2 receptors. Scand J Immunol 1991; 34: 741–52
   PubMed Web of Science ®Google Scholar
• Dohlsten M, Sjögren H O, Carlsson R. Histamine acts directly on human T cells to inhibit interleukin-2 and interferon-gamma. Cell Immunol 1987; 108: 485–92
   Google Scholar
• Bury T, Radermecker M F. Depression of polymorphonuclear chemotaxis and T-lymphocyte proliferation following histamine inhalation in man. Eur Respir J 1989; 2: 828–33
   PubMedGoogle Scholar
• Bury T, Corhay J L, Radermecker M F. Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy 1992; 47: 624–9
   PubMed Web of Science ®Google Scholar
• Schwark J C, Arrang J M, Garberg M, Polland H. A third histamine receptor subtype: characterisation, localisation and functions of the H-3 receptor. Agents Actions 1990; 30: 13–23
   PubMedGoogle Scholar
• Brandes L J, LaBella F S. Identification of intracellular histamine receptors HIC that regulate cell proliferation. Adv Biosci 1993; 89: 31–42
   Google Scholar
• Lorenz W, Röher H D, Doernicke A, Ohmann C H. Histamine release in anaesthesia and surgery: a new method to evaluate its clinical significance with several types of causal relationship. Clin Anaesthesiol 1984; 2: 403–26
   Google Scholar
• Sitter H, Lorenz W, Klotter H J, et al. Elevated plasma histamine concentration as a sensitive real-time parameter for distinct phases of the surgical trauma: a tool for technology assessment. Agents Actions 1991; 33: 203–7
   PubMedGoogle Scholar
• Falus A, Meretéy K. Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 1992; 13: 154–6
   PubMedGoogle Scholar
• Khan M M, Keaney K M, Melmon K L, Clayberger C, Krensky A M. Histamine regulates the generation of human cytolytic T lymphocytes. Cell Immunol 1989; 121: 60–73
   PubMedGoogle Scholar
• Bury T, Radermecker M F. Role of histamine in the chemotactic deactivation of polymorphonuclear leukocytes following incubation with formylmethionyl peptides. Int Arch Allergy Immunol 1992; 97: 109–14
   PubMedGoogle Scholar
• Fujimoto M, Kimata H. Histamine inhibits immuno-globulin production via histamine H-2 receptors without affecting cell growth in human B cells. Clin Immunol Immunopathol 1994; 73: 96–102
   PubMedGoogle Scholar
• Roberts Al, Leone V M, Ebert E C. Intestinal mucosal lymphocytes have H-1 receptors: H-1 antagonists reduce their proliferation and cytotoxicity. Cell Immunol 1994; 156: 212–9
   PubMedGoogle Scholar
• Hatamochi A, Fujiwara K, Ueki H. Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res 1985; 277: 60–4
   PubMed Web of Science ®Google Scholar
• Marks R M, Roche W R, Czerniecki M, Penny R, Nelson D S. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest 1986; 55: 289–94
   PubMed Web of Science ®Google Scholar
• Norrby K, Woolley D. Role of mast cells in mitogenesis and angiogenesis in normal tissue and tumour tissue. Adv Biosci 1993; 89: 71–116
   Google Scholar
• Zheng T, Nathanson M H, Elias J A. Histamine augments cytokine-stimulated IL-11 production by human lung fibroblasts. J Immunol 1994; 153: 4742–52
   PubMed Web of Science ®Google Scholar
• Mannaioni P F, Pistelli A, Gambassi F, et al. A place for free radicals in platelet-derived histamine releasing factor (PDRQ and evidence that histaminergic receptors modulate platelet aggregation. Agents Actions 1991; 33: 57–60
   PubMedGoogle Scholar
• Sipka S, Koltai M, Braquet P, Szegedi G. Histamine potentiates human platelet aggregation induced by platelet-activating factor. Int Arch Allergy Immunol 1992; 97: 89–92
   PubMedGoogle Scholar
• Mescheder A, Ebert U, Halabi A, Kirch W. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine. Eur J Clin Pharmacol 1993; 45: 151–6
   PubMedGoogle Scholar
• Dachman W D, Bedarida G, Blaschke T F, Hoffmann B B. Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol 1994; 93: 606–14
   PubMedGoogle Scholar
• Knigge U, Warberg J. The role of histamine in the neuroendocrine regulation of pituitary hormone secretion. Acta Endocrinol (Copenh) 1991; 124: 609–19
   PubMedGoogle Scholar
• Bracketl D J, Hamburger S A, Lerner M R, et al. An assessment of plasma histamine concentrations during documented endotoxic shock. Agents Actions 1990; 31: 263–74
   PubMedGoogle Scholar
• Liebman S M, Langer J C, Marshall J S, Collins S M. Role of mast cells in peritoneal adhesion formation. Am J Surg 1993; 165: 127–30
   PubMed Web of Science ®Google Scholar
• Nielsen H J. Role of histamine in the pathogenesis of autoimmune disease. Implications for drug therapy. Clin Immunother 1994; 1: 250–7
   Google Scholar
• Dabbous M K, Haney L, Nicolson G L, Eckley D, Woolley D E. Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NK. Br J Cancer 1991; 63: 873–8
   PubMedGoogle Scholar
• Watson S A, Wilkinson L J, Robertson I FR, Hardcastle J D. Effect of histamine on the growth of human gastrointestinal tumors: reversal by cimetidine. Gut 1993; 34: 1091–6
   PubMed Web of Science ®Google Scholar
• Nielsen H J. Histamine in neoplastic diseases. Histamine Symposium. Clinical and Experimental Aspects., P S Skov. The Reference Laboratory, CopenhagenDenmark 1994; 24–36
   Google Scholar
• Nonaka T, Mio M, Doi M, Tasaka K. Histamine-induced differentiation of HL-60 cells. Biochem Pharmacol 1992; 44: 1115–21
   PubMedGoogle Scholar
• Jurlander J, Brown P N, Skov P S, et al. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B-cell chronic lymphocytic leukemia. Leukemia 1995; 9: 1902–9
   PubMedGoogle Scholar
• Liotet S, Meyohas M C, Batellier L, et al. Serum histamine levels in patients with human immunodeficiency virus infection. Presse Med 1988; 17: 2240–2
   PubMedGoogle Scholar
• Burtin C, Blanche S, Galoppin L, Merval R, Griscelli C, Scheinmann P. Blood histamine levels in HIV-1-infected infants and children. Int Arch Allergy Appl Immunol 1990; 91: 142–4
   PubMedGoogle Scholar
• Rothe M J, Nowak M, Kerdel F A. The mast cell in health and disease. J Am Acad Dermatol 1990; 23: 615–24
   PubMedGoogle Scholar
• Galli S J. New concepts about the mast cell. N Engl J Med 1993; 328: 257–65
   PubMed Web of Science ®Google Scholar
• Gifford R M, Tilberg A F. Histamine type-2 receptor antagonists immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987; 102: 242–7
   PubMed Web of Science ®Google Scholar
• Jensen L S, Andersen A J, Christiansen P M, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513–6
   PubMed Web of Science ®Google Scholar
• Nielsen H J. Detrimental effects of perioperative blood transfusion. Br J Surg 1995; 82: 152–7
   Google Scholar
• Kehlet H. Modifications of responses to surgery by neural blockade and clinical implications. Neural Blockade2nd edn., M J Cousins, P Bridenbaugh. Lippincott, Boston 1987; 145–88
   Google Scholar
• Adams W J, Morris D L, Ross W B, Lubowski D Z, King D W, Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust NZ J Surg 1994; 64: 847–52
   PubMedGoogle Scholar
• Nielsen H J, Mynster T, Jensen S, Hammer J, Nielsen H. The effect of ranitidine on soluble interleukin-2 receptors and CD8 molecules in surgical patients. Br J Surg 1994; 81: 1747–51
   PubMedGoogle Scholar
• Altomare D F, Lupo L, Pannarale O C, Di Corcia M G, Memeo V. Reduction of postoperative immunosuppression with ranitidine in patients with cancer of the stomach and large bowel. Eur J Surg 1995; 161: 109–13
   PubMedGoogle Scholar
• Rasmussen L A, Nielsen H J, Serensen S, et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg 1995; 181: 138–44
   PubMedGoogle Scholar
• Nielsen H J, Witt K, Moesgaard F, Kehlet H. Ranitidine improves delayed hypersensitivity in patients with sepsis. Acta Chir Scand 1989; 155: 445–9
   PubMedGoogle Scholar
• Monson J R, Ramsden C, Guillou P J. Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 1986; 73: 483–6
   PubMedGoogle Scholar
• Tamer P I, Steinberg B, Barron D M, et al. The prognostic significance of impaired natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987; 122: 1264–8
   PubMedGoogle Scholar
• Ebert E C, Roberts A I, O'Connell M, Robertson F M, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987; 138: 2161–8
   PubMed Web of Science ®Google Scholar
• Rice S Q, Crane I J, Scully C, Prime S S. Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand J Immunol 1992; 36: 443–52
   PubMedGoogle Scholar
• Foulds S, Wakefield C H, Giles M, Gillespie J, Dye J F, Guillou P J. Expression of a suppressive p15E-related epitope in colorectal and gastric cancer. Br J Cancer 1993; 68: 610–6
   PubMedGoogle Scholar
• Blomberg J, Möller T, Olsson H, Anderson H, Jonsson M. Cancer morbidity in blood recipients - results of a cohort study. Eur J Cancer 1993; 29A: 2101–5
   PubMed Web of Science ®Google Scholar
• Kehinde E O, Petermann A, Morgan J D, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994; 81: 985–6
   PubMedGoogle Scholar
• Rosenberg S A, Yang J C, Topalian S L, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907–13
   PubMed Web of Science ®Google Scholar
• Norheim Andersen S, Rognum T O, Lund E, Meling G I, Hauge S. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993; 68: 80–5
   PubMed Web of Science ®Google Scholar
• Moesgaard F, Nielsen M L. Preoperative cell-mediated immunity and duration of antibiotic prophylaxis in relation to postoperative infectious complications. Acta Chir Scand 1989; 155: 281–6
   PubMedGoogle Scholar
• Weese J L, Ottery F D, Emoto S E. Do operations facilitate tumor growth? An experimental model in rats. Surgery 1986; 100: 273–7
   PubMed Web of Science ®Google Scholar
• Eggermont A M, Steller E P, Sugarbaker P H. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987; 102: 71–8
   PubMed Web of Science ®Google Scholar
• Lindemann F, Schlimok G, Dirshedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 685–9
   PubMed Web of Science ®Google Scholar
• Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566–71
   PubMed Web of Science ®Google Scholar
• Leather A JM, Gallegos N C, Kocjan G, et al. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg 1993; 80: 777–80
   PubMedGoogle Scholar
• Cole W H, Humphrey L. Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg 1985; 202: 9–20
   PubMedGoogle Scholar
• Moriarty C M. Histamine as a marker for solid malignant tumors. Adv Biosci 1993; 89: 289–98
   Google Scholar
• Garcia-Caballero M, Nunez de Castro I, Kusche J, Vara-Thorbeck C. Histamine metabolism in human breast and colorectal cancer. Its effects on other host tissues. Adv Biosci 1993; 89: 273–88
   Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 1990; 145: 4365–70
   PubMed Web of Science ®Google Scholar
• Fisher E R, Paik S M, Rockette H, et al. Prognostic significance of eosinophils and mast cells in rectal cancer. Hum Pathol 1989; 20: 159–63
   PubMed Web of Science ®Google Scholar
• Adams W J, Lawson J A, Morris D L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994; 35: 1632–6
   PubMed Web of Science ®Google Scholar
• Adams W J, Lawson J A, Nicholson S E, Cook T A, Morris D L. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol 1993; 19: 332–5
   PubMedGoogle Scholar
• Whitehead R J, Taylor D J, Evanson J M, Hart I R, Woolley D E. Demonstration of histamine H2 receptors on human melanoma cells. Biochem Biophys Res Commun 1988; 151: 518–23
   PubMedGoogle Scholar
• Smith T. Histamine type-2 receptor antagonists and cancer immunotherapy. Compr Ther 1990; 16: 8–13
   PubMedGoogle Scholar
• Nielsen H J, Hammer J H, Moesgaard F, Kehlet H. Possible role of histamine-2 receptor antagonists for adjuvant treatment in colorectal cancer. Eur J Surg 1991; 157: 437–41
   PubMedGoogle Scholar
• Nielsen H J, Kikuchi X. Histamine-2 receptor antagonists as potential adjuvant treatment of malignant diseases. Adv Biosci 1993; 89: 319–34
   Google Scholar
• Nielsen H J, Pedersen B K, Moesgaard F, Haahr P M, Kehlet H. Ranitidine improves postoperative depression in natural killer cell activity and delayed hypersensitivity. Acta Chir Scand 1989; 155: 377–82
   PubMedGoogle Scholar
• Nielsen H J, Hammer J H, Moesgaard F, Heron I, Kehlet H. Ranitidine improves postoperative suppression of antibody response to preoperative vaccination. Surgery 1992; 111: 69–73
   PubMedGoogle Scholar
• Nielsen H J, Nielsen H, Jensen S, Moesgaard F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg 1994; 129: 309–15
   PubMedGoogle Scholar
• Tennesen H, Knigge U, Bulow S, et al. Cimetidine improves survival in gastric cancer. Lancet 1988; 2: 990–1
   PubMedGoogle Scholar
• Adams W J, Morris D L. Short-course cimetidine and survival with colorectal cancer. Lancet 1994; 344: 1768–9
   PubMedGoogle Scholar
• Svendsen L B, Ross C, Knigge U, et al. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 1995; 38: 514–8
   PubMedGoogle Scholar
• Burtin C, Noirot C, Scheinemann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H-2 antihistaminics ranitidine and cimetidine. Eur J Cancer Clin Oncol 1988; 24: 161–7
   PubMedGoogle Scholar
• Nielsen H J, Hammer J H, Grønvall S, et al. The effect of ranitidine on immune function, tumor response and survival in patients with liver metastases from colorectal cancer. GI Cancer 1996; 1: 183–90
   Google Scholar
• Seifert R, Höher A, Schwaner I, Buschauer A. Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H-2 receptors with an unique agonist/antagonist profile and induces functional differentiation. Mol Pharmacol 1992; 42: 235–41
   PubMedGoogle Scholar
• Allen J I, Syropoulos H J, Grant B, Eagon J C, Kay N E. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med 1987; 109: 396–401
   PubMedGoogle Scholar
• Nielsen H J, Nielsen H, Moesgaard F, et al. The effect of ranitidine on cellular immunity in patients with multiple myeloma. Clin Immunol Immunother 1990; 32: 201–5
   PubMedGoogle Scholar
• Hansen M M. Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 1983; 1–286, Suppl 18
   Google Scholar
• Griffiths H, Lea J, Bunch C, Lee M, Chapel H. Predictors of infection in chronic lymphocytic leukemia CLL. Clin Exp Immunol 1992; 89: 374–7
   PubMed Web of Science ®Google Scholar
• Mellemgaard A, Brown P N, Heron I, et al. Ranitidine improves the vaccination response in patients with chronic lymphocytic leukemia - a randomized controlled study. Immunol Infect Dis 1993; 3: 109–11
   Google Scholar
• Valdimarsson H, Baker B S, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunol Today 1995; 16: 145–9
   PubMedGoogle Scholar
• Nielsen H J. Histamine and histamine type-2 receptor antagonists in psoriasis. Mechanisms and speculations. Dan Med Bull 1991; 38: 478–80
   PubMedGoogle Scholar
• Nielsen H J, Nielsen H, Georgsen J. Ranitidine for improvement of treatment-resistant psoriasis. Arch Dermatol 1991; 127: 270–1
   PubMedGoogle Scholar
• Stashower M E, Yeager J K, Smith K J, et al. Cimetidine as therapy for treatment-resistant psoriasis in a patient with acquired immunodeficiency syndrome. Arch Dermato 1993; 1(129)848–50
   Google Scholar
• Smith K C. Ranitidine is useful in the management of psoriasis in a patient with acquired immunodeficiency syndrome. Int J Dermatol 1994; 33: 220–1
   PubMedGoogle Scholar
• Witkamp L, Velthuis P J, Verhaegh M E, et al. An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis. J Am Acad Dermatol 1993; 28: 778–81
   PubMedGoogle Scholar
• Kristensen J K, Pedersen L J, Hansen U, Nielsen H, Skov P S, Nielsen H J. Systemic high-dose ranitidine in the treatment of psoriasis - an open prospective clinical study. Br J Dermatol 1995; 133: 905–8
   PubMedGoogle Scholar
• Brockmeyer N H, Kreuzfelder E, Mertins L, et al. Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol 1988; 48: 50–60
   PubMedGoogle Scholar
• Nielsen H J, Svenningsen A, Moesgaard F, et al. Ranitidine improves certain cellular immune responses in asymptomatic HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4: 577–84
   PubMedGoogle Scholar
• Miller A, Harei D, Laor A, Lahat N. Cimetidine as an immunomodulator in the treatment of herpes zoster. J Neuroimmunol 1989; 22: 69–76
   PubMedGoogle Scholar
• Feder H M. Cimetidine treatment for periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. Pediatr Infect Dis J. 1992; 11: 818–21
   Google Scholar
• Gasior-Chrzan B, Falk E S. Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists. Dermatology 1992; 184: 149–52
   PubMedGoogle Scholar
• Testa B, Mesolella C, Filippini P, et al. The role of H2 antagonists in perennial allergic rhinitis. Laryngoscope 1993; 103: 1013–9
   PubMedGoogle Scholar
• Anlar B, Gücüyener K, Imir T, Yalaz K, Renda Y. Cimetidine as an irnmunomodulator in subacute sclerosing panencephalitis: a double-blind, placebo-controlled study. Pediatr Infect Dis J 1993; 12: 578–81
   PubMedGoogle Scholar
• Meller H, Lindvig K, Klefter R, Mosbech J, Meller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1558–62
   PubMedGoogle Scholar
• La Veccia C, Negri E, D'Avanzo B, Franceshi S. Histamine-2 receptor antagonists and gastric cancer risk. Lancet 1990; 330: 355–7
   Google Scholar
• Colin-Jones D C, Langman M JS, Lawson D H, et al. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 1991; 285: 13–9
   Google Scholar
• Driks M R, Craven D E, Ceill B R, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type-2 blockers. N Engl J Med 1987; 317: 1376–82
   PubMed Web of Science ®Google Scholar
• Daon E, Summer W, Nelsen S, Mason C. Cimetidine does not impair pulmonary clearance of Pseudomonas aeruginosa in normal rats. Digest Dis Sci 1994; 39: 1469–72
   PubMedGoogle Scholar
• Simms H H, De Maria E, Mc Donald L, et al. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective, randomized trial. J Trauma 1991; 31: 531–7
   PubMed Web of Science ®Google Scholar
• Fabian T C, Boucher B A, Croce M A, et al. Pneumonia and stress ulceration in severely injured patients. A prospective evaluation of the effects of stress ulcer prophylaxis. Arch Surg 1993; 128: 185–92
   PubMedGoogle Scholar
• Martin L F, Booth F M, Karlstadt R G, et al. Continuous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993; 21: 19–30
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C H, Merki H S. Antisecretory agents in stress ulcer prophylaxis: a critical reappraisal. Eur J Gastroenterol Hepatol 1992; 4: 689–95
   Web of Science ®Google Scholar
• Merki H S, Wilder-Smith C H. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?. Gastroenterology 1994; 106: 60–4
   PubMed Web of Science ®Google Scholar
• van Zyl J M, Kriegler A, van den Walt J. Anti-oxidant properties of H2-receptor antagonists. Biochem Pharmacol 1993; 45: 2389–97
   PubMed Web of Science ®Google Scholar
• Ching T L, Haenen G R, Bast A. Cimetidine and other H2 receptor antagonists as powerful hydroxyl radical scavengers. Chem Biol Interact 1993; 86: 119–27
   PubMed Web of Science ®Google Scholar
• Ching T L, de Jong J, Bast A. Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur J Pharmacol 1994; 268: 89–93
   PubMedGoogle Scholar
• Cerutti P A, Trump B F. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991; 3: 1–7
   PubMed Web of Science ®Google Scholar
• Salim A S. Role of free radical scavengers in the management of refractory duodenal ulceration. J Surg Res 1994; 56: 45–52
   PubMedGoogle Scholar
• Cantu T G, Korek J S. Central nervous system reactions to histamine type-2 receptor antagonist infusion. Ann Intern Med 1991; 114: 1027–34
   PubMed Web of Science ®Google Scholar
• Nielsen H J. The effect of histamine-2 receptor blockade on the anti-tumor response to inlerleukin-2. Eur J Cancer 1995; 31A: 1390–1
   PubMedGoogle Scholar
• Nielsen H J, Moesgaard F, Hammer J H. Effect of ranitidine on low-dose interleukin-2 induced NK-cell activity in patients with liver metastases from colorectal cancer. Eur J Surg Oncol 1995; 21: 526–30
   PubMedGoogle Scholar
• Baba S, Ando K, Okuda K, et al. Cimetidine's inhibitory effect on recurrence of colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 219
   Google Scholar
• Allendorf J D, Bessler M, Kayton M L, Whelan R L, Treat M R, Nowygrod R. Tumor growth after laparotomy or laparoscopy. Surg Endosc 1995; 9: 49–52
   PubMedGoogle Scholar
• Nielsen H J, Edvardsen L, Dybkjasr E, Vangsgaard K, Skov P S. Time-dependent spontaneous histamine release from stored human blood products. Br J Surg 1996; 83: 259–62
   PubMedGoogle Scholar